Pacira Biosciences, Inc.
Could not find a ticker for this position, may be a filing error
Pacira BioSciences makes non-opioid pain treatments, best known for EXPAREL, a long-acting local anesthetic injected at the surgical site so patients recover from operations with less reliance on opioids. Its lineup also includes iovera°, a device that uses targeted cold to numb nerves. Founded in 2006 under the placeholder name Blue Acquisition Corp., the Tampa-based company later renamed itself Pacira and rebranded as Pacira BioSciences in 2019.
0.75% Convertible Senior Notes due August 1, 2025
Bought 997.3K · Sold 1.53M
Bought 535.7K
Bought 535.7K · Sold 382.9K
Bought 843.4K · Sold 909.1K
Bought 461.5K
Sold 500.0K
Bought 997.3K · Sold 500.0K
Bought 535.7K
Sold 290.9K
Sold 500.0K
Bought 277.9K · Sold 220.0K
Granted 711.3K · Bought 8.3K
Bought 843.4K · Sold 3.06M
Sold 250.0K
Granted 1.18M · Bought 5.0K · Sold 900.3K
Granted 224.8K · Sold 19.4K
Granted 221.7K · Sold 45.2K
Granted 113.8K · Sold 8.7K
Granted 174.1K · Sold 62.1K
Granted 106.1K
Granted 71.2K · Sold 21.1K
Granted 82.5K · Bought 2.5K · Sold 52.4K
Granted 65.9K · Sold 11.1K
Bought 267.9K
Sold 374.5K
Granted 113.2K · Sold 73.8K
Granted 33.5K · Sold 12.3K
Granted 41.4K · Bought 5.5K · Sold 15.9K
Sold 2.3K
Granted 61.8K · Bought 1.0K · Sold 32.7K
Granted 34.5K · Sold 5.0K
Granted 128.9K · Sold 101.1K
Granted 28.0K · Bought 1.5K · Sold 2.2K
Granted 256.0K · Sold 230.6K
Granted 201.3K · Bought 10.0K · Sold 187.0K
Granted 23.1K
Granted 109.5K · Sold 93.8K
Granted 150.8K · Bought 27.2K · Sold 154.3K
Granted 19.8K · Bought 2.0K · Sold 768
Granted 17.8K · Bought 2.0K
Granted 47.8K · Bought 300 · Sold 29.3K
Granted 17.8K · Bought 4.9K · Sold 4.9K
Granted 17.8K
Granted 16.3K · Bought 1.5K · Sold 1.6K
Granted 56.6K · Sold 45.4K
Granted 13.2K
Granted 32.5K · Sold 35.8K
Granted 49.3K · Bought 853 · Sold 37.4K
Granted 11.4K · Sold 2.4K
Granted 112.8K · Bought 230 · Sold 104.5K
Granted 4.8K · Bought 2.6K
Granted 6.4K
Granted 4.5K · Sold 373
Granted 180.0K · Sold 179.7K
Granted 48.8K · Sold 48.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Evnin LukeDirector · 24 transactions | — | 21.11Mas of Jun 2013 | — | 997.3K | 1.53M |
| Dombkowski Ashley L +9 co-filers10% owner · 4 transactions | — | 9.36Mas of Feb 2011 | — | 535.7K | — |
| Isaly Samuel D +2 co-filers10% owner · 25 transactions | — | 5.18Mas of Mar 2012 | — | 535.7K | 382.9K |
| HBM Bioventures Cayman LTD10% owner · 8 transactions | — | 3.43Mas of Mar 2013 | — | 843.4K | 909.1K |
| Foley Todd +8 co-filers10% owner · 1 transaction | — | 3.29Mas of Nov 2011 | — | 461.5K | — |
| Foley Todd +7 co-filersFormer 10% Owner · 1 transaction | — | 2.79Mas of Mar 2013 | — | — | 500.0K |
| Gadicke Ansbert +1 co-filerFormer 10% Owner · 6 transactions | — | 2.79Mas of Mar 2013 | — | 997.3K | 500.0K |
| Gordon Carl LDirector · 8 transactions | — | 2.65Mas of Feb 2011 | — | 535.7K | — |
| HBM Healthcare Investments (Cayman) Ltd.10% owner · 3 transactions | — | 2.23Mas of Mar 2013 | — | — | 290.9K |
| Middleton Fred A +5 co-filersDirector, 10% owner, 10% owner · 2 transactions | — | 1.34Mas of Apr 2013 | — | — | 500.0K |
| Middleton Fred ADirector · 31 transactions | — | 1.07Mas of Jun 2013 | — | 277.9K | 220.0K |
| Lee Frank D.Chief Executive Officer, Director · 7 transactions | — | 660.8K | 711.3K | 8.3K | — |
| Wicki AndreasDirector · 86 transactions | — | 451.3Kas of Mar 2021 | — | 843.4K | 3.06M |
| Middleton Fred A +5 co-filersDirector · 10 transactions | — | 416.1Kas of Mar 2013 | — | — | 250.0K |
| Stack David MCEO and Chairman, Director · 157 transactions | — | 302.7Kas of Jun 2023 | 1.18M | 5.0K | 900.3K |
| Slonin JonathanChief Medical Officer · 28 transactions | — | 218.9K | 224.8K | — | 19.4K |
| Williams KristenChief Administrative Officer · 12 transactions | — | 167.1K | 221.7K | — | 45.2K |
| Gaugler DarylChief Operating Officer · 17 transactions | — | 115.4Kas of Dec 2024 | 113.8K | — | 8.7K |
| Cross ShawnChief Financial Officer · 16 transactions | — | 105.3K | 174.1K | — | 62.1K |
| Teehan BrendanChief Commercial Officer · 4 transactions | — | 100.9K | 106.1K | — | — |
| Riker LaurenSenior Vice President, Finance · 15 transactions | — | 62.3K | 71.2K | — | 21.1K |
| Winston RoyChief Medical Officer · 29 transactions | — | 52.4Kas of Aug 2023 | 82.5K | 2.5K | 52.4K |
| Reinhart Charles A. IIIChief Financial Officer · 16 transactions | — | 51.9Kas of Jun 2024 | 65.9K | — | 11.1K |
| Sanderling VI Beteiligungs GmbH & Co KG +4 co-filers10% owner · 20 transactions | — | 48.7Kas of Mar 2013 | — | 267.9K | — |
| Middleton Fred A +4 co-filersDirector, 10% owner, 10% owner · 17 transactions | — | 42.8Kas of Apr 2013 | — | — | 374.5K |
| Laranjeira Charles AnthonyChief Technical Officer · 24 transactions | — | 41.8Kas of Jun 2022 | 113.2K | — | 73.8K |
| McLoughlin DennisChief Customer Officer · 11 transactions | — | 38.1Kas of Jun 2023 | 33.5K | — | 12.3K |
| Kronenfeld Mark A.Director · 20 transactions | — | 31.1Kas of Jun 2025 | 41.4K | 5.5K | 15.9K |
| Ellis Ronald J. Jr.Chief Strategy Officer · 2 transactions | — | 30.9Kas of Jun 2023 | — | — | 2.3K |
| Brege LauraDirector · 24 transactions | — | 30.1K | 61.8K | 1.0K | 32.7K |
| Manning Donald C.Chief Medical Officer · 4 transactions | — | 29.5Kas of Jun 2021 | 34.5K | — | 5.0K |
| Reinhardt MaxPresident, Rest of World · 26 transactions | — | 29.2Kas of Jun 2023 | 128.9K | — | 101.1K |
| Froimson MarkDirector · 16 transactions | — | 26.5K | 28.0K | 1.5K | 2.2K |
| Williams Kristen MarieChief Administrative Officer · 84 transactions | — | 25.4Kas of Jun 2023 | 256.0K | — | 230.6K |
| Scibetta James SPresident · 42 transactions | — | 25.1Kas of Jun 2017 | 201.3K | 10.0K | 187.0K |
| Christie ChristopherDirector · 7 transactions | — | 23.1K | 23.1K | — | — |
| Riker Lauren BullaroSenior Vice President, Finance · 81 transactions | — | 22.7Kas of Jul 2023 | 109.5K | — | 93.8K |
| Pace Gary WDirector · 32 transactions | — | 22.1Kas of Mar 2024 | 150.8K | 27.2K | 154.3K |
| Braunstein ScottSVP, Strategy & Corp. Dev. · 4 transactions | — | 21.0Kas of Jun 2017 | 19.8K | 2.0K | 768 |
| Yang Michael J.Director · 4 transactions | — | 19.8K | 17.8K | 2.0K | — |
| Longenecker John P PHDDirector · 37 transactions | — | 18.8Kas of Mar 2022 | 47.8K | 300 | 29.3K |
| Bigal MarceloDirector · 6 transactions | — | 17.8K | 17.8K | 4.9K | 4.9K |
| Young AlethiaDirector · 3 transactions | — | 17.8K | 17.8K | — | — |
| Jones James BSVP & Chief Medical Officer · 6 transactions | — | 16.8Kas of Nov 2017 | 16.3K | 1.5K | 1.6K |
| Scranton RichardChief Scientific Officer · 13 transactions | — | 16.1Kas of Nov 2019 | 56.6K | — | 45.4K |
| Greenstreet YvonneDirector · 8 transactions | — | 13.2Kas of Jun 2022 | 13.2K | — | — |
| Molloy AnthonyChief Lgl & Compliance Officer · 17 transactions | — | 12.9Kas of Jun 2023 | 32.5K | — | 35.8K |
| Hastings Paul JDirector · 42 transactions | — | 12.7Kas of Jun 2024 | 49.3K | 853 | 37.4K |
| Ceesay AbrahamDirector · 3 transactions | — | 9.0K | 11.4K | — | 2.4K |
| Markvicka TauniaSVP, Chief Commercial Officer · 13 transactions | — | 8.8Kas of Mar 2015 | 112.8K | 230 | 104.5K |
| Winger Dennis LDirector · 4 transactions | — | 7.5Kas of Jun 2017 | 4.8K | 2.6K | — |
| Hirawat SamitDirector · 1 transaction | — | 6.4K | 6.4K | — | — |
| Weiland Robert J.Chief Commercial Officer · 2 transactions | — | 5.1Kas of Jun 2018 | 4.5K | — | 373 |
| Patou GaryChief Medical Officer · 28 transactions | — | 2.6Kas of Aug 2014 | 180.0K | — | 179.7K |
| Pratt JohnGeneral Manager, San Diego · 12 transactions | — | 0as of Jun 2013 | 48.8K | — | 48.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.67M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.